{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kim JY"],"funding":["National Research Foundation of Korea (NRF)","National Cancer Center","National Cancer Center (NCC)","Korea Health Industry Development Institute","National Research Foundation of Korea","Korea Health Industry Development Institute (KHIDI)"],"pagination":["239"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8924236"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(3)"],"pubmed_abstract":["Ovarian carcinoma (OC) is the most lethal gynecological malignancy due to frequent recurrence resulting from cisplatin-resistance. ARL6IP5 is a novel gene implicated to suppress cisplatin-resistance by activating apoptosis and inhibiting DNA repair through XRCC1 and PARP1. We investigated the clinicopathological and prognostic significance of the immunohistochemical ARL6IP5 expression on 79 post-chemotherapy OC patient tissue samples; in vitro, the effect of ARL6IP5 overexpression (OE) and knockdown (KD) on cancer hallmark functions and the effect of ARL6IP5 on the expression of DNA repair and apoptosis-related proteins were observed in OC cells and their cisplatin-resistant (CisR) counterparts. ARL6IP5 expression was significantly associated with chemotherapeutic response and was an indep"],"journal":["Cell death & disease"],"pubmed_title":["ARL6IP5 reduces cisplatin-resistance by suppressing DNA repair and promoting apoptosis pathways in ovarian carcinoma."],"pmcid":["PMC8924236"],"funding_grant_id":["2018R1C1B5043725","2016R1D1A1B03935584","2019R1FA1059148","HI21C1137","NCCCDA2018-04"],"pubmed_authors":["Yoon H","Kim SH","Kim JY","Bahar E","Kim HS","Park EY","Do SI","Chang S","Lee JY"],"additional_accession":[]},"is_claimable":false,"name":"ARL6IP5 reduces cisplatin-resistance by suppressing DNA repair and promoting apoptosis pathways in ovarian carcinoma.","description":"Ovarian carcinoma (OC) is the most lethal gynecological malignancy due to frequent recurrence resulting from cisplatin-resistance. ARL6IP5 is a novel gene implicated to suppress cisplatin-resistance by activating apoptosis and inhibiting DNA repair through XRCC1 and PARP1. We investigated the clinicopathological and prognostic significance of the immunohistochemical ARL6IP5 expression on 79 post-chemotherapy OC patient tissue samples; in vitro, the effect of ARL6IP5 overexpression (OE) and knockdown (KD) on cancer hallmark functions and the effect of ARL6IP5 on the expression of DNA repair and apoptosis-related proteins were observed in OC cells and their cisplatin-resistant (CisR) counterparts. ARL6IP5 expression was significantly associated with chemotherapeutic response and was an indep","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-22T18:17:50.905Z","creation":"2025-04-06T02:24:48.333Z"},"accession":"S-EPMC8924236","cross_references":{"pubmed":["35293383"],"doi":["10.1038/s41419-022-04568-4"]}}